There is strong evidence to support a major role for vimentin in the regulation of cancer growth, showing a higher protein expression level in metastatic prostate cancer patients with a Docetaxel resistance [30], in the context of the EMT phenotype [31]. This evidence concerns the gene VIM and metastatic prostate carcinoma.